Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Limiting AKI Progression In Sepsis (LAPIS): A Phase 4, Multicenter, Randomized Controlled Trial of Biomarker-guided Delivery of Kidney-sparing Care Measures in Sepsis Subjects at Risk of Developing AKI

NCT04434209 is registered in ClinicalTrials.gov with BioMérieux as lead sponsor.

NCT NCT04434209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04434209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Limiting AKI Progression In Sepsis (LAPIS): A Phase 4, Multicenter, Randomized Controlled Trial of Biomarker-guided Delivery of Kidney-sparing Care Measures in Sepsis Subjects at Risk of Developing AKI
Lead sponsor
BioMérieux
Phase
Not applicable
Overall status
Terminated
Start date
January 19, 2021
Completion date
February 14, 2022
Enrollment
19 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, sepsis, septic shock